The place of meldonium in complex treatment of patients with comorbidity of chronic pancreatitis and stable coronary heart disease

Rezumat

Metabolic therapy is one of few ways to recreate normal work of all vital organs and systems. The aim of the work was to examine the efficiency of protracted treatment with metabolic medication Vazonat (meldonium dihydrate) on the correction of the prooxidant-antioxidant and trophological violation in patients with comorbide course of chronic pancreatitis (CP) and stable coronary artery disease (SCAD). The study included 90 patients with CP and SCAD who were divided into two groups: I group (45 patients) received standard treatment (ST); II group (45 patients) except ST additionally received meldonium according to the following sketch: 5ml intravenously once a day during 10 days with its succeeding receiving of 250 mg twice a day in capsules during one month. It was proved that adding meldonium to the complex treatment of the patients with CP and SCAD comorbidity greatly assists improving of the indices of trophological and prooxidant-antioxidant in comparison with general basic therapy.